Characterization of heterogeneity in the molecular pathogenesis of lupus nephritis from transcriptional profiles of laser-captured glomeruli

Karin S. Peterson, …, Michael R. Jackson, Robert J. Winchester

*J Clin Invest.* 2004;113(12):1722-1733. [https://doi.org/10.1172/JCI19139](https://doi.org/10.1172/JCI19139).

The molecular pathogenesis of focal/diffuse proliferative lupus glomerulonephritis was studied by cDNA microarray analysis of gene expression in glomeruli from clinical biopsies. Transcriptional phenotyping of glomeruli isolated by laser-capture microscopy revealed considerable kidney-to-kidney heterogeneity in increased transcript expression, resulting in four main gene clusters that identified the presence of B cells, several myelomonocytic lineages, fibroblast and epithelial cell proliferation, matrix alterations, and expression of type I IFN–inducible genes. Glomerulus-to-glomerulus variation within a kidney was less marked. The myeloid lineage transcripts, characteristic of those found in isolated activated macrophages and myeloid dendritic cells, were widely distributed in all biopsy samples. One major subgroup of the samples expressed fibrosis-related genes that correlated with pathological evidence of glomerulosclerosis; however, decreased expression of TGF-β1 argued against its role in lupus renal fibrosis. Expression of type I IFN–inducible transcripts by a second subset of samples was associated with reduced expression of fibrosis-related genes and milder pathological features. This pattern of gene expression resembled that exhibited by activated NK cells. A large gene cluster with decreased expression found in all samples included ion channels and transcription factors, indicating a loss-of-function response to the glomerular injury.

Find the latest version:

[http://jci.me/19139-pdf](http://jci.me/19139-pdf)
Characterization of heterogeneity in the molecular pathogenesis of lupus nephritis from transcriptional profiles of laser-captured glomeruli

Karin S. Peterson, Jing-Feng Huang, Jessica Zhu, Vivette D’Agati, Xuejun Liu, Nancy Miller, Mark G. Erlander, Michael R. Jackson, and Robert J. Winchester

The molecular pathogenesis of focal/diffuse proliferative lupus glomerulonephritis was studied by cDNA microarray analysis of gene expression in glomeruli from clinical biopsies. Transcriptional phenotyping of glomeruli isolated by laser-capture microscopy revealed considerable kidney-to-kidney heterogeneity in increased transcript expression, resulting in four main gene clusters that identified the presence of B cells, several myelomonocytic lineages, fibroblast and epithelial cell proliferation, matrix alterations, and expression of type I IFN–inducible genes. Glomerulus-to-glomerulus variation within a kidney was less marked. The myeloid lineage transcripts, characteristic of those found in isolated activated macrophages and myeloid dendritic cells, were widely distributed in all biopsy samples. One major subgroup of the samples expressed fibrosis-related genes that correlated with pathological evidence of glomerulosclerosis; however, decreased expression of TGF-β1 argued against its role in lupus renal fibrosis. Expression of type I IFN–inducible transcripts by a second subset of samples was associated with reduced expression of fibrosis-related genes and milder pathological features. This pattern of gene expression resembled that exhibited by activated NK cells. A large gene cluster with decreased expression found in all samples included ion channels and transcription factors, indicating a loss-of-function response to the glomerular injury.

Introduction

Systemic lupus erythematosus (SLE) is a genetically determined autoimmune disease in which a T cell–driven adaptive immune response results in the formation of autoanti bodies, most notably directed against DNA, RNA, and their associated proteins (1, 2). Classically, the resulting immune complexes have been considered to initiate renal disease, one of the most significant causes of morbidity and mortality in lupus, through complement activation in a neutrophil-mediated Arthus-type reaction. However, evidence from studies of spontaneous lupus in the New Zealand Black/White (NZB/W) mouse has indicated involvement of other pathways, including activation of myeloid cells via Fc receptor engagement, that are thought to mediate the inflammatory response (3).

The pathological manifestations of lupus nephritis are diverse, variably affecting the different renal compartments, including glomeruli, tubules, interstitium, and vasculature (4). Lupus glomerular injury takes several forms and is categorized into five classes: WHO classes I–V (4). A major feature of lupus nephritis is the considerable degree of variation in severity of histopathological involvement between different glomeruli from the same biopsy, and the histopathological classification is therefore based on the average score for all glomeruli in the biopsy. The most common and most severe forms, focal (class III) and diffuse (class IV) proliferative glomerulonephritis, share similar histopathological features and differ principally by the proportion and extent of glomerular involvement.

Importantly, the course, response to therapy, and outcome are heterogeneous among affected individuals, with nearly one in three progressing to glomerulosclerosis and end-stage renal disease, while the others either respond to therapy or follow a milder course (4). These differences in outcome are not well correlated with WHO class (4). Efforts at better predicting outcome and therapeutic requirements from biopsy morphology were initiated by Pollack et al., whose distinction of active and sclerosing lesions led to the development of the activity and chronicity indices (5, 6). Although there is a positive correlation of elevated chronicity index with progression to chronic renal insufficiency, the lack of a clear threshold value, low sensitivity, and problems in reproducibility have limited the utility of the morphological indices (7). These points raise the question of whether there are additional differences not identified at the level of conventional histopathology that are relevant to the nature of the renal injury and emphasize the need to analyze the pathogenesis of lupus nephritis at the molecular level.

The application of the microarray technique to the monitoring of gene expression profiles has provided significant insights into the biology of different neoplasms and has demonstrated its value in the approach to their subclassification (8). However, there are significant problems raised by the application of this methodology to lupus nephritis. First, the architecture of the kidney is complex and
different structural regions of the kidney exhibit distinctive gene expression profiles (9). Because lupus nephritis affects each compartment of the kidney in different ways, with the most profound primary immune complex injury at the level of the glomerulus, it is advantageous to study glomerular gene expression separately from that of the interstitium and tubules. Second, the potential for inflammation-related alterations in multiple renal cell lineages and the presence of infiltrating inflammatory cells complicate the interpretation of the results. Finally, only the limited “archival material” remaining after diagnostic renal biopsy interpretation is available for research purposes, constraining the scope of potential studies. The technology described by Luo et al. (10) that integrates laser-capture microscopy of individual cells with linear RNA amplification and cDNA microarray analysis offers an approach for overcoming these limitations. This combined technology recently has been applied to the analysis of malignant and premalignant tissues (11–13). In the present study, we first sought to determine the feasibility of using laser-captured human glomeruli to examine the gene expression profiles of archival clinical lupus biopsies. In addition, we wished to determine whether microarray analysis could assist in the identification of molecular processes underlying lupus glomerular disease, with the ultimate goal of identifying molecular pathways and their heterogeneity that may be responsible for specific disease features and their relationship to the autoimmune process.

**Results**

Hierarchical clustering of genes differentially expressed in SLE glomeruli compared with controls. Glomeruli were isolated successfully from the surrounding tissue by laser-capture microscopy, as documented by microscopic visualization of glomeruli before and after laser capture (Figure 1), and the transcriptional phenotypes of the glomeruli were determined using amplified RNA in microarray analyses. Compared
with the mean value of expression in controls, SLE glomeruli exhibited one large cluster of genes with increased expression and one with decreased expression in each of two independent and separately processed and analyzed sets of lupus glomeruli studied on different cDNA microarrays (Figure 2A). Because of the high degree of similarity between the corresponding separate hierarchical clusters, the 88 genes with increased expression in the two data sets were merged and analyzed by hierarchical clustering (Figure 2B). Four main gene clusters with increased expression were identified (Supplemental Table 1; supplemental material available at http://www.jci.org/cgi/content/full/113/12/1722/DC1) and analyzed in detail (see below) for identification of their possible biological significance. Although the number of cDNAs on the microarray was limited and not inclusive of all possible genes in the clusters, we were able to discern biological characteristics likely related to function in each cluster. Briefly, seven of the eleven genes in cluster I were characterized by the presence of type I IFN response elements. Approximately half of the genes in cluster II contained transcripts that indicated the presence of cells of the myelomonocytic lineage in the glomerulus, and two of four genes in the small cluster III were expressed specifically in B cells. Cluster IV was characterized by the fact that more than one third of the transcripts were involved in the production or regulation of extracellular matrix (ECM), and this cluster appeared likely to be linked to the glomerulosclerosis (fibrosis) of lupus nephritis. Each transcript has been identified by its corresponding gene symbol as contained in LocusLink, which also includes the primary references to individual genes (14).

The large cluster of genes with decreased expression in lupus glomeruli, compared with that of controls, was in general uniformly decreased across all samples (Figure 2A). The transcripts included transcription factors and ion channels or were involved in aspects of cellular growth and differentiation (Supplemental Table 1). Some genes encoded molecules whose function in the kidney is not established. Unexpectedly, given their increased expression in some forms of glomerulosclerosis other than lupus (15, 16), both TGF-B1 (TGF-β1) and two of its receptor molecules, TGF-BR2 and TGF-BR3, exhibited significantly decreased expression in SLE glomeruli compared with controls, as did plasminogen activator inhibitor type 1 (PAI-1 or SERPINE; Figure 2A). Of note also was the decreased expression of transcripts involved in endothelial proliferation and angiogenesis, including VEGF, VEGFR1 (Flt1), and FGF1, particularly as endocapillary proliferation is a morphologic characteristic of class III/IV lupus nephritis (Table 1).
Gene expression profiles of glomeruli isolated from the same biopsy cluster together. As illustrated by the sample dendrogram in Figure 2B, different glomeruli obtained from the same patient biopsy were more concordant in their overall expression profiles than were glomeruli from different biopsies. Notably, in the case of biopsies 9 and 38, different glomeruli obtained from the same biopsy clustered together even when analyzed in the independent data sets B12 and B13, despite some differences in expression intensity. The paired glomeruli from biopsies 90 and 87 shared the expression of certain clusters but differed markedly in the expression of others.

Increased expression of genes with type I IFN response elements. Gene cluster I comprised 11 transcripts, most of which contained type I IFN response elements. Gene expression profiles of glomeruli from the same biopsy cluster expressed by SLE glomeruli. Myelomonocytic cell lineage, and SP100, a nuclear autoantigen and transcriptional activator, are notable markers of the fibrosis group.

Gene expression profiles of glomeruli isolated from the same biopsy cluster together. As illustrated by the sample dendrogram in Figure 2B, different glomeruli obtained from the same patient biopsy were more concordant in their overall expression profiles than were glomeruli from different biopsies. Notably, in the case of biopsies 9 and 38, the gene expression profiles of glomeruli from the same biopsy clustered together even when analyzed in the independent data sets B12 and B13, despite some differences in expression intensity. The paired glomeruli from biopsies 69, 109, and 114 were also concordant in their overall gene expression. Conversely, the paired glomeruli from biopsies 68, 87, and 90 shared the expression of certain clusters but differed markedly in the expression of others, notably those of the fibrosis group.

Cluster II was the most widely distributed cluster expressed by SLE glomeruli. Myelomonocytic cell lineage, and SP100, a nuclear autoantigen and transcriptional activator, are notable markers of the fibrosis group.

Increased expression of genes with type I IFN response elements. Gene cluster I comprised 11 transcripts, most of which contained type I IFN response elements, and included G1P2 (ISG15), a ubiquitin-like molecule, and IFIT1, encoding the intracellular p56 protein, which inhibits protein synthesis. MX1 and MX2 are two large GTPases that belong to the dynamin family of microtubule-binding proteins; their specific function in man is not known in detail. MNDA (myeloid cell nuclear differentiation antigen) encodes a nuclear protein that promotes differentiation of the myeloid lineage, and SP100, a nuclear autoantigen and transcriptional enhancer. KIAA1268 exhibits significant DNA sequence homology to an IFN-α-induced gene identified in the rainbow trout (17). Only thromboxane A2 receptor (TBX2AR2), adenylsuccinate synthase (ADSS), prostasin (PRSS8), and the NCK adaptor protein 1 (NCK1) in this cluster lack IFN response elements.

A cell reference panel was used in an effort to identify patterns of infiltrating cell lineages among the glomerular expression profiles. A number of resting and activated peripheral blood cell cultures had been analyzed by microarray, and their expression profiles were linked by their gene identities to those of the glomerular samples, as shown in Figure 3. The top part of Figure 3 illustrates the overlap in expression between the transcripts of cluster I and the peripheral blood reference panel and demonstrates a strong expression of all cluster I genes by LPS-activated NK cells (CD56), but not by unstimulated NK cells. Some of the transcripts with type I IFN response elements were also expressed at lower levels by activated CD4 cells and cells of the neutrophil lineage.

Increased expression of genes related to myelomonocytic and other inflammatory cells. Cluster II was the most widely distributed cluster expressed by SLE glomeruli. Myelomonocytic cell lineage marker genes characterized this cluster and included CD14, CD40 (TNFRSF5), CD18 (ITGB2), CD53, C3 receptor (C3AR1), Toll-like receptor 2 (TLR2), and two components of the microbicidal oxidase system, NCF2 and CYBB. The mitogen-induced chemokine MIP-1-α (CCL3), involved in the recruitment and

Table 2
Clinical data for SLE patients studied by renal biopsy

<table>
<thead>
<tr>
<th>Patient characteristics</th>
<th>Biopsy identifier</th>
<th>Age/sex</th>
<th>Ethnicity</th>
<th>Diagnosis of SLE (mo)</th>
<th>Diagnosis nephritis (mo)</th>
<th>Major extrarenal manifestations of SLE</th>
<th>WHO nephritis class</th>
<th>Glom. IgG deposition</th>
<th>Glom. IgM deposition</th>
<th>Anti-DNA (&lt;35)</th>
<th>Complement</th>
<th>Hemoglobin (g/l)</th>
<th>Serum Cr mg/dl</th>
<th>Urinalysis</th>
<th>Medications prior to biopsy</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>119</td>
<td>27 yr/F</td>
<td>A</td>
<td>11</td>
<td>Arthritis, Interstitial pneumonia, Rash, ITP</td>
<td>IV</td>
<td>1+</td>
<td>0</td>
<td>92</td>
<td>Low</td>
<td>11.1 (12–16)</td>
<td>1.2 (0.9)</td>
<td>E3+</td>
<td>Plaq Cyt x1 Pred Plaq Pred, Aza</td>
</tr>
<tr>
<td></td>
<td></td>
<td>72</td>
<td>22 yr/F</td>
<td>B</td>
<td>24</td>
<td>Arthritis, rash, None</td>
<td>IV</td>
<td>3+</td>
<td>3+</td>
<td>82</td>
<td>Low</td>
<td>13.1 (12–16)</td>
<td>1.8 (0.9)</td>
<td>8.6</td>
<td>Pred Pred Plaq Pred, Aza</td>
</tr>
<tr>
<td></td>
<td></td>
<td>109</td>
<td>22 yr/F</td>
<td>H</td>
<td>1</td>
<td>Arthritis, rash, None</td>
<td>IV</td>
<td>5</td>
<td>5</td>
<td>62</td>
<td>Low</td>
<td>12.7 (12–16)</td>
<td>1.2 (0.9)</td>
<td>9.06</td>
<td>Pred Pred Plaq Pred, Aza</td>
</tr>
<tr>
<td></td>
<td></td>
<td>114</td>
<td>22 yr/F</td>
<td>H</td>
<td>3</td>
<td>Arthritis, rash, None</td>
<td>IV</td>
<td>2+</td>
<td>2+</td>
<td>19</td>
<td>Low</td>
<td>8.7 (12–16)</td>
<td>2.2 (0.9)</td>
<td>0.96</td>
<td>Pred Pred Plaq Pred, Aza</td>
</tr>
<tr>
<td></td>
<td></td>
<td>117</td>
<td>18 yr/F</td>
<td>B</td>
<td>6</td>
<td>Arthritis, rash, None</td>
<td>IV</td>
<td>2+</td>
<td>3+</td>
<td>21</td>
<td>19</td>
<td>8.7 (12–16)</td>
<td>2.2 (0.9)</td>
<td>4</td>
<td>Pred Pred Plaq Pred, Aza</td>
</tr>
<tr>
<td></td>
<td></td>
<td>69</td>
<td>27 yr/F</td>
<td>B</td>
<td>24</td>
<td>Arthritis, rash, None</td>
<td>IV</td>
<td>3+</td>
<td>3+</td>
<td>113</td>
<td>21</td>
<td>9.5 (12–16)</td>
<td>1.8 (0.9)</td>
<td>5.9</td>
<td>Pred Pred Plaq Pred, Aza</td>
</tr>
<tr>
<td></td>
<td></td>
<td>9</td>
<td>28 yr/F</td>
<td>C</td>
<td>4</td>
<td>Arthritis, rash, None</td>
<td>IV</td>
<td>3+</td>
<td>3+</td>
<td>39</td>
<td>39</td>
<td>7.9 (12–16)</td>
<td>0.8 (0.9)</td>
<td>11</td>
<td>Pred Pred Plaq Pred, Aza</td>
</tr>
<tr>
<td></td>
<td></td>
<td>68</td>
<td>28 yr/F</td>
<td>H</td>
<td>2</td>
<td>Arthritis, Rash, Pancytopenia</td>
<td>III</td>
<td>1+</td>
<td>1</td>
<td>7.9</td>
<td>11</td>
<td>7.4 (12–16)</td>
<td>1.1 (0.9)</td>
<td>5.5</td>
<td>Pred Pred Plaq Pred, Aza</td>
</tr>
<tr>
<td></td>
<td></td>
<td>90</td>
<td>45 yr/F</td>
<td>A</td>
<td>1</td>
<td>Arthritis, rash, alopecia</td>
<td>III</td>
<td>1+</td>
<td>1</td>
<td>1.3</td>
<td>7.9</td>
<td>13.7 (12–16)</td>
<td>0.5 (0.9)</td>
<td>&gt;2.0</td>
<td>Pred Pred Plaq Pred, Aza</td>
</tr>
<tr>
<td></td>
<td></td>
<td>87</td>
<td>10 yr/M</td>
<td>H</td>
<td>2</td>
<td>Arthritis, rash, alopecia</td>
<td>III</td>
<td>1+</td>
<td>1+</td>
<td>5.5</td>
<td>7.9</td>
<td>10.1 (12–16)</td>
<td>0.5 (0.9)</td>
<td>None</td>
<td>Pred Pred Plaq Pred, Aza</td>
</tr>
<tr>
<td></td>
<td></td>
<td>38</td>
<td>28 yr/M</td>
<td>A</td>
<td>2</td>
<td>Arthritis, rash, alopecia</td>
<td>IV</td>
<td>3+</td>
<td>3+</td>
<td>300</td>
<td>38</td>
<td>1.2 (12–16)</td>
<td>1.1 (0.9)</td>
<td>3.3</td>
<td>Pred Pred Plaq Pred, Aza</td>
</tr>
<tr>
<td></td>
<td></td>
<td>93</td>
<td>10 yr/M</td>
<td>H</td>
<td>1</td>
<td>Arthritis, rash, alopecia</td>
<td>IV</td>
<td>3+</td>
<td>3+</td>
<td>58</td>
<td>58</td>
<td>1.2 (12–16)</td>
<td>1.1 (0.9)</td>
<td>None</td>
<td>Pred Pred Plaq Pred, Aza</td>
</tr>
</tbody>
</table>

Note: SLE, systemic lupus erythematosus; WHO, World Health Organization; Glom., glomerular; Cr, creatinine; Pred, prednisone; Plaq, plaquenil; Cyt, cyclophosphamide; ×1, once; Aza, azathioprine; Nl, normal; ITP, immune thrombocytopenia. Blank sections, information not available.

aMeasured in months (mo) prior to the date of the renal biopsy. bPresence of IgG and IgM heavy chains and complement components C1 and C3, as determined by immunofluorescence staining of all biopsies (scale, 0–3+). cAll laboratory values were obtained at time of renal biopsy. Normal values are given in parenthesis for anti-DNA, hemoglobin, and serum creatinine. dAnalyzed by measurement of CH50 and/or C3 and C4. eThe 24-hour urine proteins in grams are given when available; if not, the qualitative urinalysis by dipstick is listed (scale, 1+ to 4+). fDiscoid lupus erythematosus (DLE) was diagnosed 60 months prior to the onset of SLE. H, Hispanic; B, black; C, Caucasian; A, Asian; Glom., glomerular; Cr, creatinine; Pred, Prednisone; Plaq, plaquenil; Cyt, cyclophosphamide; ×1, once; Aza, azathioprine; Nl, normal; ITP, immune thrombocytopenia. Blank sections, information not available.
activation of various inflammatory cells, was a highly expressed chemokine, along with Eta-1 (osteopontin; SPP1), a cytokine that is involved in early activation by T cells.

Pathways involved in the cellular uptake of antigen and immune complexes were suggested by a set of transcripts including CD36, CD163, FCGBP, and FCER1G. CD36 is a thrombospondin receptor that also functions as a scavenger receptor (18), and CD163 is a putative scavenger receptor present on myeloid cells. FCGBP is a mucin-rich IgG Fc receptor (FcγR) and FCER1G (Fcγc) is the signaling γ-chain that is common to several of the Fc receptors (FcRs).

Also increased in expression were LYN and HCK, encoding two Src family kinases that are activated upon FcγR stimulation (19). Several transcripts indicated activation of the lysosomal antigen presentation pathway, including the lysosomal enzymes legumain (LGMN), cathepsin B (CTSB), cathepsin H (CTSH) and IFI30. The last encodes an IFN-γ-induced lysosomal thiol reductase (GILT) whose expression is essential for antigen presentation by MHC class II molecules and normal immune function (20).

It is clear from the gene expression profiles that the myeloid-related transcripts vary in their expression across lupus glomeruli, although elements of cluster II were present in almost all samples (Figure 2B), suggesting a heterogeneous pattern of infiltrating myeloid cells of different lineages and activation states. Additional evidence for the potential presence of a diverse set of myeloid cells was obtained by analyses of the parallels in expression between known genes in cluster II and the cell reference panel (Figure 3, II). Expression profiles characteristic of activated and resting neutrophils, monocytes, and dendritic cells could be identified among lupus-associated glomerular transcripts. However, individual cell lineages could not be assigned with certainty, as only a few transcripts were specific for an individual cell type; for example, Eta-1, expressed by dendritic cells. Few transcripts were specific for T cells, among them MAL, a marker of the differentiated T cell lineage, which clustered with the myeloid transcripts. Analysis of expression of the lupus-associated transcripts by the peripheral blood reference set also demonstrated a paucity of T cell profiles in glomeruli, and the...
activated CD4 cell was the only lineage that exhibited considerable overlap in gene expression (Figure 3).

The small but distinctive gene cluster III mainly reflected the presence of transcripts identifying immunoglobulin heavy (IGHG3) and light (IGL) chains and, as illustrated by Figure 3, this cluster was specifically expressed by B cells in the reference panel.

Increased expression of genes related to ECM and glomerulosclerosis. Gene cluster IV contained a set of transcripts known to be involved in the production or regulation of ECM that are likely to be involved in elements of the inflammatory response leading to lupus renal fibrosis and included lumican (LUM), collagen I and VI (COL1A2 and COL6A3), and matrilysin (MMP7). Epithelial proliferation and increased numbers of fibroblasts are additional features of fibrosis, and several transcripts in cluster IV indicated the presence of these two processes: desmoplakin (DSP) is involved in the formation of epithelial sheets and keratin 18 (KRT18) is an intermediate filament of simple epithelia. THY1 is a fibroblast marker and FAP is a fibroblast-activating protein not expressed by normal adult tissue but synthesized by reactive stromal fibroblasts in healing wounds.

Interestingly, this cluster also contains CCL2, encoding monocyte chemoattractant protein 1 (MCP-1), a chemokine previously linked to renal fibrosis (21). Other transcripts encode proteins that are related to inflammation and not known to be directly involved in the process of fibrosis, such as the arachidonate 5-lipooxygenase-activating protein (ALOX5AP), complement C3, C1r (C1R), and I factor (IF), and a hematopoietic transcription factor, RUNX1. Cathepsin C (CTSC) was highly and consistently present among these transcripts.

Except for CCL2, which is expressed mainly by activated monocytes, and RUNX1, few genes that were also expressed by cells in the blood reference panel (Figure 3, IV), suggesting that the majority of the cluster IV transcripts were derived from parenchymal cells. The source of MCP-1 (CCL2) is ambiguous, as the mesangial cell has been shown to synthesize this chemokine after exposure to inflammatory or mechanical injury (22).

Characterization of molecular heterogeneity among lupus glomeruli. Although all lupus biopsies in this study were classified as WHO class III or WHO class IV and in all but two instances were obtained from patients with clinical renal disease with a duration of 1 month...
or less (Table 2), they exhibited a distinct heterogeneity in gene expression, as illustrated in Figure 2B. Analysis of the variance in gene expression between biopsies, with grouping of all glomeruli from each biopsy, using a nested ANOVA algorithm (23) (data not illustrated) identified two main biopsy subgroups, designated SG1 and SG2. Hierarchical clustering of transcripts differentially expressed by these two subgroups demonstrated that biopsies in the SG1 group were characterized by strong expression of several genes in the fibrosis cluster, whereas the SG2 biopsies were distinguished by high expression of most of the transcripts previously identified as containing type I IFN response elements and low expression of the fibrosis-related genes that characterized SG1 biopsies (Figure 4).

Molecular heterogeneity was also examined at the level of the individual glomerulus. A scoring system was used to determine the presence or absence of a specific gene cluster to each glomerular sample (Figure 5). Transcripts with type I IFN response elements were concordantly expressed by all glomeruli in seven of twelve biopsies and were absent in all glomeruli in the remaining five samples. All but one glomerulus across all twelve biopsies were classified as expressing the fibrosis-related transcripts were distinguished as expressing the fibrosis-related transcripts were distinguished by higher scores of the activity and chronicity indices, including cellular crescents, fibrous crescents, and wire loops. However, the presence of the fibrosis cluster was not uniformly associated with necrosis. Interestingly, the expression of B cell genes by glomeruli paralleled the extent of histologic infiltration by CD3 T cells.

Relationship of molecular phenotype with histopathological studies. Study of the relationship between the presence or absence of a specific gene cluster with the immunopathological findings of the biopsies revealed no overall correlation between activity and chronicity indices and gene expression (Table 3). However, there were a number of correlations with elements of the indices and individual gene clusters. All biopsies were also studied by immunohistochemistry using CD3 and CD68 staining (Table 1 and Figure 7), and these features of the biopsy were included in the correlations with individual gene clusters.

The expression of the genes with type I IFN response elements was associated with lower scores for three elements of the activity and chronicity indices: neutrophil infiltration, cellular crescents, and fibrous crescents. Moreover, these glomeruli were characterized by significantly smaller infiltration of CD3 T cells by histological scores. In contrast, renal biopsies containing glomeruli classified as expressing the fibrosis-related transcripts were distinguished by higher scores of the activity and chronicity indices, including cellular crescents, fibrous crescents, and wire loops. However, the presence of the fibrosis cluster was not uniformly associated with higher scores, as there was a trend toward decreased occurrence of necrosis.
glomerular histopathological involvement within a kidney. We within a kidney than between kidneys, despite the variation in relatively less glomerulus-to-glomerulus molecular heterogeneity are variably present in lupus nephritis. Interestingly, there was inconsistent with a unitary pattern of Arthus reaction–mediated expression of four main gene clusters, with each gene cluster analyses by the two methods correlating significantly (Figure 6).

frozen within 1–2 hours of being obtained. Given the minute quanti such as the renal interstitium and tubules. This work demonstrated that regularly processed clinical biopsies could be used if they were frozen within 1–2 hours of being obtained. Given the minute quantities of RNA obtained, linear amplification of RNA was an essential step for transcript quantification by microarray analysis. There is considerable support for the sensitivity and reproducibility of laser-capture microdissection and T7 promoter–based RNA amplification in the detection of transcription profiles even down to the single-cell level (24). In the present study, two lines of work supported the consistency of the results. First, the similarity of findings between two semi-independent data sets included in this analysis (Figure 2) allowed a degree of cross-validation showing that technical factors had minimal influence and supporting the choice to pool the two datasets for the main analysis. Second, the level of transcript expression for three informative genes was independently validated by qRT-PCR analysis using nonamplified RNA as the starting material, with analyses by the two methods correlating significantly (Figure 6).

A dominant feature of this study was the considerable degree of heterogeneity between lupus kidney biopsies in the increased expression of four main gene clusters, with each gene cluster reflecting the contribution of different pathways relevant to glomerular inflammation. These divergent features appear highly inconsistent with a unitary pattern of Arthus reaction–mediated necrosis and indicate that several different pathogenic elements are variably present in lupus nephritis. Interestingly, there was relatively less glomerulus-to-glomerulus molecular heterogeneity within a kidney than between kidneys, despite the variation in glomerular histopathological involvement within a kidney. We anticipate that the differences in these molecular patterns found in different kidneys will elucidate some of the marked heterogeneity in clinical outcome of lupus glomerulonephritis, but the design of this study did not allow this question to be addressed. However, the potential significance of each gene cluster to different pathological aspects of lupus nephritis was supported by the finding of associations of particular clusters with some elements of the activity and chronicity indices. No association was found, however, between transcriptional profiles and the WHO class III and IV subdivision of glomerulonephritis, indicating that similar molecular pathogenic processes characterize the two classes and that both exhibited equivalent heterogeneity in their transcriptional phenotype. A number of genes were consistently reduced in expression across all glomeruli, including ion channels and transcription factors, suggesting a loss-of-function response to the glomerular inflammation.

The observed heterogeneity in gene expression among glomeruli in different biopsies (Figures 2 and 4) raises the important question of whether these differences identify subtypes of lupus nephritis or are a reflection of different stages in the progression of lupus nephritis. In support of the former possibility, both the SG1 and SG2 subgroups (Figure 4) had an equivalently high proportion of class IV proliferative nephritis, similar deposition of immune complexes and complement components, and in serum, similarly elevated antibodies to DNA and lowered complement levels (Table 2). The identical, relatively short mean duration of disease in both the SG1 and SG2 subgroups and comparable therapy in both groups prior to biopsy argues that the observed differences in transcriptional phenotype mainly reflect heterogeneity in the mechanisms of proliferative glomerulonephritis. However, serial gene expression profiles should be studied in consecutive renal biopsies to define more precisely the changes that occur in time. The trend toward mean higher serum creatinine levels in individuals with the SG1 classification of gene expression probably reflected a consequence of the processes occurring in the glomeruli.

The use of microarrays is a powerful tool for hypothesis generation that can lead to false-positive as well as false-negative conclusions, so it is imperative to cross-validate the present findings in a new study comprising a totally independent cohort of lupus glomeruli. It should be stressed, however, that the criteria used to select genes for clustering in this study were intentionally conservative, such as the requirement of a twofold change of expression in at least one third of lupus samples and control of the false discovery rate to less than 0.05. This resulted in the identification of fewer genes but at correspondingly greater levels of confidence.

The most widespread pattern of elevated gene expression in lupus glomeruli was for a large cluster of transcripts identified as being expressed mainly by cells of the myeloid lineage. We attempted to identify the particular myeloid lineages present in the glomerulus by using a peripheral blood reference panel and obtained evidence that was compatible with the presence of activated monocytes/macrophages, activated dendritic cells, and activated neutrophils (Figure 3). However, it was not possible to clearly distinguish the lineages present in the glomeruli due to the large number of genes with overlapping expression among the various myeloid cell types. These findings emphasize the importance and the complexity of the myeloid lineages found in the nephritic kidney and they are consistent with observations in the NZB/W mouse model of spontaneous lupus-like nephritis (3, 25).

The myeloid subcluster that included CD14 exhibited more variation in glomerular expression than the myeloid cluster and correlated with certain features within the activity index, including cellular crescents, endocapillary proliferation, and wire loops, but not with others, such as necrosis (Table 3), which suggests that a particular subset or activation pattern of macrophages accounts for certain features present in active lupus nephritis. The transcriptional signature of the myeloid subcluster also correlated with immunohistochemical staining by CD68, providing an additional cross-validation of the microarray results. These findings are consistent with the proposed inclusion of increased macrophage numbers in a modified activity index proposed by Hill et al. (7) and emphasize the importance of this lineage in lupus glomerulonephritis.
Signaling through the activating FeRγc chain is central to the immune complex–mediated glomerular injury that occurs in the NZB/W mouse model of lupus nephritis (3). It was therefore especially interesting to find an increase in the expression of FeRγc in the CD14 myeloid subcluster, suggesting that a similar pathway of macrophage activation may occur in the human disease. Expression of the “classic” FcRs that signal through FeRγc has been difficult to demonstrate in the glomerulus and is an area of investigation (26). In this context, it is intriguing to find increased expression of FCGBP (Fcγ-binding protein), an FcR previously unknown in the kidney and previously identified only on placenta and colonic epithelium (27). The increased glomerular expression of other cell surface receptors such as CD36 and CD163 suggests additional pathways that may be involved in the handling of glomerular immune complexes.

T cells infiltrate the kidney in lupus nephritis (28), and small numbers were clearly identified in most glomeruli by immunohistochemistry (Table 1 and Figure 7B); however, relatively few T cell lineage genes were identified by microarray analysis. This low number may reflect the strict selection criteria used for clustering analysis and may be a false-negative finding. However, the increased expression of transcripts in the pathway of MHC class II antigen presentation suggests a glomerular potential to present peptide (auto-) antigens to T cells. The presence in the glomerulus of a small cluster of genes characterizing B cells and plasma cells correlated with numbers of glomerular T cells, and in turn with high scores for interstitial inflammation and crescents (Table 3) suggests that these lymphocytes are present in concert with these processes, as has been observed in the NZB/W mouse during nephritis (25). This raised the possibility that cognate T cell–B cell interaction possibly driven by autoantigen recognition occurs in the kidney and could enhance both glomerular injury and the autoimmune response. The finding of increased expression of the IFN-γ–induced IFI30 and of Eta-1 in lupus glomeruli together with decreased expression of TGF-β point to an environment that would favor Th1 cell differentiation. Eta-1 has been associated with the development of Th1-mediated immunity (29). IFN-γ has been identified as a major effector molecule that drives the development of lupus in murine models of the disease (30). While the role of the T cell in the nephritic glomerulosclerosis remains incompletely documented in these microarray experiments, it was interesting to find a relative accumulation of CD3+ cells in periglomerular interstitial regions of the lupus biopsies that were studied by microarray (Figure 7B), raising the separate question of why T cells preferentially accumulate in the interstitium.

Global glomerulosclerosis or fibrosis characterizes end-stage renal disease regardless of specific etiology, and a clinically important issue in lupus nephritis is to identify the individuals who will probably progress to renal fibrosis. The observation that in different biopsies the expression of the fibrosis cluster correlated with the presence of crescents and the hyaline matrix deposition of wire loops (Table 3) suggests that these transcripts indeed mediate certain elements of glomerulosclerosis. Interestingly, although there was one instance of divergent glomerulus-to-glomerulus expression of the fibrosis genes, in most biopsies, the pattern of fibrotic gene expression was usually found in both glomeruli with morphological evidence of sclerosis and glomeruli with minimal or no involvement at the morphological level. This suggests that the early identification of this pattern in glomeruli with little histopathological evidence of frank glomerulosclerosis or crescent formation may denote an individual at high risk of progression to this response.

Transcripts for collagen I α2 and collagen VI α3 are increased in lupus glomeruli as part of the fibrosis cluster. Both transcripts are also increased in diabetic glomerulosclerosis and crescentic glomerulonephritis through a pathway involving TGF-β1 (16, 20, 25). Intriguingly, in terms of the mechanism of fibrosis in lupus, the present study suggests it does not occur through a TGF-β1–mediated pathway, as lupus glomeruli exhibit a striking decrease in expression of TGF-β1 and two of its receptor proteins, as well as the TGF-β1–induced PAI-1 (15). Conversely, there are several genes that could play a role in regulating the development of lupus glomerulosclerosis: MCP-1 is highly expressed in the fibrosis-related cluster and has previously been linked to some forms of nephropathy (21), and the increase in matrilysin (MMP7) is significant, as MMP7 promotes fibrosis in interstitial pneumonitis (31).

Another member of the fibrosis cluster is RUNX1, encoding a hematopoietic transcription factor that is emerging as a central transcriptional regulator in autoimmune disease. The RUNX1 product interacts with PDCD1, located at chromosome 2q37 and encoding a transcript that regulates programmed cell death. PDCD1 has been identified as a strong candidate gene for increasing susceptibility to SLE (32) through a single-nucleotide polymorphism that alters a RUNX1 binding site. Recently, susceptibility to rheumatoid arthritis (33) and to psoriasis (34) were also shown to be associated with genes that contained altered binding sites for RUNX1 and that were encoded by loci located at chromosomes 5q31 and 17q25, respectively.

One of the more striking features of lupus glomeruli was the pattern of high expression of genes with promoters containing type I IFN response elements that was found in approximately half of the biopsies and accounted for most of the genes in the SG2 subgroup. The expression of these transcripts was highly concordant among all glomeruli from the same biopsy, suggesting that an extravascular process may regulate their presence in the kidney. Although the expression of genes with type I IFN response elements in lupus glomeruli could be responsible for glomerular injury in the SG2 group, their presence in these glomeruli was inversely correlated with that of many genes in the fibrosis cluster and with the presence of cellular and fibrous crescents, otherwise considered as histological elements indicating a “high-risk” of lupus nephritis (35). This suggests that an event related to the expression of these transcripts might either cause a milder form of renal injury or be a protective response to glomerular injury. If protective, however, the presence of fibrosis-related transcripts in a few of the SG2 glomeruli emphasizes that the protection from glomerulosclerosis is not absolute.

In terms of the mechanism responsible for the coordinate induction of the genes containing type I IFN response elements in glomeruli, there was no evidence of elevated glomerular levels of IFN-α transcripts, although IFN-α is elevated in peripheral blood of some individuals with SLE (36, 37). Moreover, preliminary data demonstrate that the increased expression of type I IFN–inducible transcripts by the SG2 group of lupus biopsies (Figure 4) is restricted to the glomerulus, as qRT-PCR analyses of ISG15 and MX1 in renal interstitial tissue was markedly lower than in the corresponding glomerulus (data not shown). This also emphasizes the technical importance of studying gene expression in individual renal compartments.

Recently it was demonstrated that type I IFN–inducible transcripts are increased in peripheral blood leukocytes of some individuals with active lupus (38, 39), and it is possible that this elevation could parallel the glomerular increase in type I IFN–inducible transcripts observed in this study. The present finding that activated NK cells...
express all of the type I IFN response element–containing transcripts that were identified in lupus glomeruli suggests one additional interpretation of this “signature” in the kidney: that the entrance of activated NK cells could be responsible for this phenotype, mediating either an injurious or a protective effect. This is supported by the finding that a few genes not containing type I IFN response elements were also included in this cluster and were increased in NK cells. Perhaps also related to this is the observation that some type I IFN–inducible transcripts identified in this study were located in genomic regions associated with the lupus susceptibility. MNDa is found in the lupus susceptibility region at 1q22 (40), and ifi202, a murine homolog of MNDa that is encoded by a region syntenic to 1q22, is an interesting gene indicating susceptibility to lupus in the mouse (41). A second IFN–inducible gene, SP100, is located within another region associated with lupus susceptibility in the human genome, at 2q36-37 (40). This aspect of the action of some type I IFN–inducible transcripts may be relevant to the development of autoimmune phenomena that occasionally appear during the use of IFN–α in the treatment of chronic viral hepatitits and certain malignancies (42). However, until the significance of the expression of type I IFN–inducible genes in lupus is better understood, some caution may be warranted if considering blockade of IFN–α induction as a therapeutic target.

Methods

Clinical samples. The biopsies were from individuals with SLE who had newly identified renal involvement leading to diagnostic renal biopsy and for which there was abundant residual “archival” frozen tissue (Table 2). Controls were kidney biopsies that appeared normal by histopathological examination. These were either from kidneys in which there was minimal isolated proteinuria or hematuria but no pathological abnormalities were identified by renal biopsy, or from uninvolved portions of a kidney at the time of nephrectomy for tumor. One study population (called B13) included 11 individuals with lupus nephritis (17 independently processed glomeruli) and 2 control individuals (3 independently processed glomeruli). A second sample set (called B12) included eight glomeruli isolated from three SLE biopsies and three control glomeruli from two different control individuals. Some SLE biopsies, represented by different glomeruli, were studied in both sample sets. The two sample sets were processed at different times and were analyzed on slightly different versions of the cDNA microarray, as indicated in Methods, cDNA microarray. All biopsies had been stored at –80°C from several months to more than a year before being processed for microarray analyses, and only those biopsies that had been frozen within approximately 1 hour of collection were used for laser capture. Standard histological, immunofluorescence, and electron microscopy studies were used to classify the biopsies (Table 1) (4, 6). Quantification of infiltrating T cells (CD3) and macrophages (CD68) was done using immunoperoxidase staining of formalin-fixed tissue. For gene expression analyses, if more than one glomerulus was analyzed from the biopsy, each glomerulus was isolated by laser-capture microscopy, processed, and analyzed individually by microarray hybridization. The use of “archival” renal biopsies and clinical data reported in this study were approved by the Columbia University Institutional Review Board (IRB 0144).

Laser-capture microscopy and RNA/cDNA sample preparation. For each glomerular sample, four to six sections 7 μm in thickness of a frozen biopsy were used for laser capture of consecutive levels of the same glomerulus. Approximately 1–5 ng of RNA were extracted from each laser-captured glomerular sample. After two rounds of T7 promoter–based RNA amplification, each sample typically provided a final yield of 50–100 μg of amplified mRNA (10, 24). Because of the potential for transcript truncation or degradation, no sample was processed further unless the adequacy of each amplification was verified by quantitative PCR amplification of aliquots of RNA removed prior to and after each step in the amplification process using primers specific for proximal and distal exons of a ubiquitous eukaryotic elongation factor (EEF1A1) as described (24). The overall quality of the amplified RNA was also assessed by agarose gel electrophoresis (data not shown).

cDNA microarray. The human cDNA microarrays were spotted onto Corning GAPS slides (Corning Life Sciences, Acton, Massachusetts, USA) using an Amersham Biosciences Generation III spotter (Amersham Biosciences, Piscataway, New Jersey, USA). The B12 array contained 3,602 genes and the B13 array had the same 3,602 genes plus an additional 428 genes. Each clone was spotted in duplicate on the array. Of the clones on the array, 39% were IMAGE clones purchased from Research Genetics (Invitrogen, Carlsbad, California, USA). The microarrays contained a set of expressed human genes that were chosen based on the availability of human cDNA clones at that time rather than their functional characteristics. The major functional families of cDNAs on the microarray included receptor molecules (25% of clones), ion channels (6.5% of clones), immunoglobulin family (1% of clones), cytokines and chemokines (3.3% of clones), enzymes (18% of clones), adhesion molecules (4% of clones), transporters (5% of clones), signal transduction molecules (5% of clones), DNA-binding molecules (2.6% of clones), and chaperones (3.2% of clones). The indocarbocyanine-labeled cDNA probe preparation, hybridization, and subsequent washes of the arrays were performed according to the methods described by Luo et al. (10). The arrays were scanned in a ScanArray 4000 (Perkin Elmer Life Sciences, Boston, Massachusetts, USA). Quantification was done using Imagene (Biodiscovery, Marina del Rey, California, USA).

Quantitative PCR analysis. Total RNA was extracted from two to four laser-captured glomeruli isolated as described above using the Qiagen Micro RNA kit (Qiagen Inc., Valencia, California, USA). Total RNA was converted to cDNA without prior amplification of RNA using the First Strand Synthesis System (Invitrogen) and an oligo(dT) primer. The cDNA (0.4 μl for each reaction) was subjected to SYBR green–based qRT-PCR using a Smart Cycler (Cepheid, Sunnyvale, California, USA) according to the manufacturer’s instructions. The target CTSC, ISG15, and MX1 genes were amplified using the following primers: for CTSC, CAGACCAAGATCTCAAGCCCTCAG (5’S) and GCCATAGCCCAAGACAGAAACG (3’S); for ISG15, GGCGGCCAAGATTTCCAGGGTG (5’S) and CTCGGCCGAGGCGAGATTCA (3’S); and for MX1, TGCTGCATCCACCCCTTTATACTT (5’S) and GGCATGGCGATTCTGGCCGTAT (3’S). Amplification of the reference gene EEF1A1 using primers CATGCAAGTTTGCTGAGCTG (5’S) and GGCATGGCGATTCTGGCCGTAT (3’S) and of a negative control was included in each experiment in separate reactions. Because the quantity of the template was limited, DNase treatment was not performed and instead the two primers were designed so that the target cDNA spanned at least one intron in the genomic sequence. The qRT-PCR reaction was performed in the presence of 20 mM Tris–HCl, pH 8.4, 50 mM KCl, 3 mM MgCl₂, 0.2% Tween-20, 0.15 M Trehalose, 0.2 mg/ml BSA,
cells in the presence of LPS. Activated B cells were prepared by incubation of CD19 cells overnight in CD40-coated wells or in the presence of PMA. CD4 T cells and CD8 T cells were activated by overnight culture in the presence of OKT3 (mouse monoclonal antibody to human CD3) and CD28. RNA extraction, cDNA probe preparation, and cDNA microarray hybridization were done as described below, with the exception that RNA was not amplified prior to cDNA synthesis.

Selection of genes that differ in expression between SLE glomeruli and controls. Transcripts unlikely to contribute significantly to the differential gene expression profiles of the two groups of glomeruli were filtered out first by determination of the difference in gene expression between lupus glomeruli and controls on the final normalized data for each gene on the microarray using a Welch modified t test (S-PLUS 2000; Insightful, Seattle, Washington, USA). A Benjamini and Hochberg (45) stepwise procedure was used to control the false discovery rate below 0.05. Genes with adjusted P values greater than 0.05 were considered not to have significant differences between SLE and controls and were removed from further analysis.

The second selection step was based on calculation of the log ratio of expression between experiment and control for each gene, using for the control value the expression of the gene averaged across all controls (C-avg.). As the expression values were already “log transformed,” this ratio was obtained by subtraction of C-avg. from the log expression value of the gene in each sample. In this selection step, we included only genes that had a change in this log ratio of at least a twofold in one third or more of the SLE glomeruli, resulting in 177 genes that were selected for subsequent cluster analysis.

Cluster analysis. The log ratios for the expression of each of the 177 genes, as defined above, were clustered in the OmniViz version 3.0 software (OmniViz Inc.). An agglomerative hierarchical cluster analysis was performed using average linkage and a correlation metric unless otherwise stated.

Subgrouping of SLE samples and selection of subgroup-specific genes. The variance of each gene among the 11 different SLE biopsies in set B13 was estimated individually by a nested ANOVA model (S-PLUS 2000; Insightful); the structure of the data was biopsy/glomerular sample. Using this model, genes with high biopsy-to-biopsy variance were selected (P ≤ 0.05) and the ratio of the expression in each SLE glomerulus to the mean expression in the controls was calculated for each gene and was analyzed by hierarchical clustering. This identified the two biopsy subgroups designated SG1 and SG2.

Differential gene expression between SG1 and SG2 was then determined for each gene by nested ANOVA using the structure SLE subgroup/biopsy/glomerular sample. The Benjamini and Hochberg procedure was further applied to keep the false discovery rate below 0.05 (45). Genes were selected based on adjusted P values of 0.05 or less and a ratio of twofold or more between the mean of the expression in SG1 versus SG2. For the selected genes, the ratio of their expression in each SLE glomerulus over the mean of the controls was analyzed by hierarchical clustering using average linkage and a Euclidean correlation metric.

Expression of individual gene clusters in each glomerular sample and the correlation to histopathological markers of disease. To obtain an overall measure of the expression of a gene cluster by individual glomeruli, we calculated the mean value of the intensity scores (log ratio of expression in a lupus sample over geometric mean of controls) for all genes in the cluster. A value of 0.6 or more (equal to a change of approximately 1.5-fold over controls) was used to indicate expression of a cluster by a glomerular sample. The semiquantitative
morphological variables (immunopathology and markers of activity and chronicity) characterizing each glomerular sample were then compared between the group of glomeruli expressing a certain gene cluster and the group not expressing the gene cluster using the Wilcoxon rank sum test in SPSS.

Acknowledgments
Ann Moriarty, Didier Leturcq, and Juli DeGraw (Johnson & Johnson Pharmaceutical Research and Development) are gratefully acknowledged for allowing us to use data from their unpublished microarray analyses of a set of peripheral blood cell cultures. We also thank Valeria Streshkeno for performing the qRT-PCR analyses; Lin Luo and Anton Bittner for excellent technical assistance; and Fredrik Kamme and Xiao-Jun Ma for valuable discussions.

This study was in part supported by grants from the United States Institute of Health (P30 HD34611, K01 DK002853, U19 AI046132, and K12 HD43389).

Received for publication June 6, 2003, and accepted in revised form April 9, 2004.

Address correspondence to: Karin S. Peterson, Department of Pediatrics, Columbia University, PH4–477, 630 168th Street, New York, New York 10032, USA. Phone: (212) 305-5766; Fax: (212) 305-9078; E-mail: ksp4@columbia.edu.

Mark Erlander’s present address is: Arcturus Applied Genomics, Carlsbad, California, USA.